beta
/Haite Biotech: 2025 Board of Directors Work Report
NEWS

Haite Biotech: 2025 Board of Directors Work Report

Shenzhen Stock Exchange
2026/04/24

Wuhan Haite Biopharmaceutical Co., Ltd.

2025 Board of Directors Work Report

In 2025, the board of directors of Wuhan Haite Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") strictly complied with the "Company Law", "Securities Law", "Shenzhen Stock Exchange GEM Stock Listing Rules" and "Shenzhen Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 2" No. - Standardized Operation of GEM Listed Companies" and other laws and regulations as well as relevant provisions of the "Company Articles", "Board of Directors Rules of Procedure" and other rules and regulations, in line with the attitude of being responsible to all shareholders, earnestly perform the board of directors' responsibilities assigned by the shareholders' meeting, conscientiously implement the resolutions of the shareholders' meeting, actively promote the work of the board of directors, constantly standardize the company's corporate governance structure, and carry out various tasks diligently and diligently, laying a good foundation for the company's sustainable and healthy development. The work of the company’s board of directors in 2025 is now reported as follows:

1. Overall operating situation of the company during the reporting period

In 2025, the company will strictly follow the annual business plan, actively implement the board of directors' decisions and strategic deployment, and promote the smooth development of various tasks. In 2025, after the company's consolidated statements, the company achieved total operating income of 541.4498 million yuan, a decrease of 16.57% from the same period last year, and a net profit attributable to shareholders of the listed company of -231.2657 million yuan, a decrease of 233.48% from the same period last year. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -254.6864 million yuan, a decrease of 145.54% compared with the same period last year.

During the reporting period, the company continued to work around the two main business lines of drug manufacturing and R&D services, and continued to develop in the production and sales of innovative biological drugs and CRO services for chemical drugs.

2. Work of the Board of Directors in 2025

(1) Board of Directors meetings

In 2025, the company's board of directors held a total of 5 board meetings based on actual production and operation conditions, and reviewed and approved 24 proposals. The organization, holding and voting procedures of the meeting are in compliance with relevant regulations such as the Company Law and the Articles of Association. All directors of the company attended each meeting, and all resolutions at the meeting were reviewed and approved. The details of the meeting are as follows:

Serial number Meeting session Convening time Proposal

1 The second meeting of the ninth session of the Board of Directors 2025.4.17 1. "Proposal on the <2024 General Manager Work Report>" meeting 2. "Proposal on the <2024 Board of Directors Work Report>" 3. "Proposal on the <2024 Financial Final Account Report>"

  1. "Proposal on the <Full Text and Summary of the 2024 Annual Report>" 5. "Proposal on the <2025 First Quarter Report>"

  2. "Proposal on the <2024 Profit Distribution Plan>"

  3. "Proposal on the "Special Report on the Storage and Use of Raised Funds in 2024"

  4. "Proposal on the <2024 Internal Control Self-Evaluation Report>"

  5. "Proposal on Renewing the Audit Institution for 2025"

  6. "Proposal on Confirming the Remuneration of the Company's Directors, Supervisors, and Senior Management Personnel for 2024 and the Remuneration Plan for 2025"

  7. "Proposal on Changes in Accounting Policies"

  8. "Proposal on Convening the Annual Shareholders Meeting in 2024" 2 Third Session of the Ninth Board of Directors 2025.4.30 1. "Proposal on the Establishment of a "

meetings

3 The Fourth Meeting of the Ninth Session of the Board of Directors 2025.8.25 1. "Agenda Meeting on the Full Text and Summary of the 2025 Semi-annual Report"

  1. "Proposal on the "Special Report on the Deposit, Management and Use of Funds Raised in the Half-Year of 2025"

4 Fifth Session of the Ninth Board of Directors 2025.10.22 1. "Proposal on the <Third Quarterly Report of 2025>"

Meeting 2. "Proposal on Amending the Articles of Association and Handling Industrial and Commercial Registration" 3. "Proposal on Establishing, Revising and Abolishing Part of the Company's Governance System"

  1. "Proposal on Provision for Goodwill Impairment"

5 ". Proposal on authorizing the company's management to initiate the preparatory work related to the company's overseas issuance of shares (H shares) and listing on the Stock Exchange of Hong Kong Limited"

6 ". Proposal on Proposing to Convene the First Extraordinary General Meeting of Shareholders in 2025"

5 The Sixth Session of the Ninth Session of the Board of Directors 2025.12.29 1. "Proposal on the Election of Independent Directors"

2nd meeting 2. "Proposal on changing the use of part of the raised funds and closing some of the raised investment projects and permanently replenishing working capital with the remaining raised funds" 3. "Proposal on using idle self-owned funds for cash management"

(2) Convening of shareholders’ meetings and implementation of resolutions

In 2025, the company held a total of 1 annual shareholders' meeting and 1 extraordinary shareholders' meeting. company board of directors

Strictly comply with the Company Law, Securities Law and other relevant laws and regulations as well as the Articles of Association and Rules of Procedure of the Board of Directors.

"Principles", strictly abide by the resolutions and authorizations of the shareholders' meeting, and conscientiously implement all decisions reviewed and approved by the shareholders' meeting.

meetings to ensure that all resolutions are fully implemented to protect the legitimate rights and interests of all shareholders. The specific situation is as follows:

Serial number Meeting session Convening time Proposal

1 2024 Annual Shares 2025.05.13 1. "Proposal on the <2024 Board of Directors Work Report>"

Eastern Conference 2. "Proposal on the "2024 Work Report of the Board of Supervisors"

  1. "Proposal on the <2024 Financial Final Account Report>"

  2. "Proposal on <Full Text and Summary of the 2024 Annual Report>"

  3. "Proposal on the <2024 Profit Distribution Plan>"

  4. "Proposal on Renewing the Audit Institution in 2025"

  5. "Proposal on Confirming the Remuneration of the Company's Directors, Supervisors, and Senior Management in 2024 and the Remuneration Plan for 2025"

2 The first time in 2025 2025.11.07 1. "Proposal on Amending the Articles of Association and Handling Industrial and Commercial Registration"

Extraordinary Shareholders Meeting 2. "Proposal on Establishing, Revising and Abolition of Part of the Company's Governance System"

(3) Performance of duties of each special committee of the board of directors

During the reporting period, the special committees of the company's board of directors performed their duties conscientiously, actively carried out various tasks, and fully

It performs specialized deliberation functions to ensure the scientific nature of the board of directors' decisions and improve the quality of the company's major decisions. 2025

In 2017, each special committee of the company's board of directors reviewed regular reports, storage and use of raised funds, and elections.

Regarding independent directors and other matters, the Nomination Committee, the Remuneration and Appraisal Committee once, and the Audit Committee held four meetings were held.

committee.

Committee name meeting

Member status Meeting session Date of meeting Contents of meeting

Weigh times

Nomination Committee Members Mao Zongfu, Ran Nomination for the Ninth Board of Directors 1. "About Nomination for the Company's Ninth Board of Directors" 1 2025.12.29

Meeting Mingdong, Yan Jie The second meeting of the committee "Proposal on the establishment of director candidates"

Remuneration of the Ninth Board of Directors 1. "About Confirmation of the Company's Directors, Remuneration and Examination for 2024" Zhou Haibing, Mao

1 and Appraisal Committee No. 1 2025.4.15 Supervisors, Senior Management Remuneration and 2025 Appraisal Committee Zong Fu, Xian Wen

Meeting Proposal on Annual Remuneration Plan

  1. "Financial Accounts Report for 2024" 2. "Full Text and Summary of the Annual Report for 2024"

  2. "2025 First Quarter Report" 4 ". Deposit and use of raised funds in 2024 Audit by the Ninth Board of Directors

Special report on the situation on 2025.4.15》

Second meeting of the committee

5 ". 2024 Internal Control Self-Evaluation Report Ran Mingdong, Zhou

Audit Committee Report》

Hai Bing, Zhu Family 4

Meeting 6. "About Re-appointment of Audit Institution Phoenix for 2025"

motion"

  1. "Proposal on Changes in Accounting Policies" considers the following proposals:

1《. Full text of the 2025 semi-annual report and its excerpts Audit of the Ninth Board of Directors

2025.8.22 Want》

Third meeting of the committee

  1. "Special Report on the Deposit, Management and Use of Raised Funds in the Half-Year 2025"

Consider the following motions:

Audit of the Ninth Board of Directors 1. "Third Quarterly Report 2025" 2025.10.17

The Fourth Meeting of the Committee 2. "Proposal on Provision for Goodwill Impairment"

Consider the following motions:

  1. "Proposal on using idle self-owned funds to manage the audit funds of the current ninth session of the Board of Directors"

2025.12.29

The Fifth Meeting of the Committee 2. "Proposal on Changing the Use of Part of the Raised Funds, Closing Some Raised Investment Projects and Permanently Replenishing Working Capital with the Surplus Raised Funds"

(4) Duty performance of independent directors

During the reporting period, the company's independent directors strictly followed the requirements of the Company Law, the Securities Law, the Measures for the Administration of Independent Directors of Listed Companies, the Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies, the Articles of Association and other relevant laws, regulations and normative documents. They performed their duties conscientiously, diligently and prudently in their work in 2025, actively attended meetings of the board of directors and shareholders, carefully reviewed various proposals, expressed independent opinions on major matters of the company, and gave full play to the role of independent directors and various special committees.

On the one hand, the company's independent directors strictly review relevant matters submitted to the board of directors by the company, safeguard the legitimate rights and interests of the company and public shareholders, promote the company's standardized operations, and safeguard the overall interests of the company and the interests of all shareholders, especially small and medium-sized shareholders; on the other hand, they give full play to their professional advantages, actively pay attention to and participate in research on the company's development, and provide constructive opinions and suggestions for the company's audit and internal control construction, salary incentives, nominations and appointments, strategic planning and other work.

(5) Information disclosure and inside information management

During the reporting period, the company strictly complied with the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other relevant laws and regulations and the "Articles of Association", conscientiously fulfilled its information disclosure obligations, completed regular report disclosures on time, and issued temporary announcements in a true, accurate, complete and timely manner based on the company's actual situation. The company registers and reports insiders of inside information in accordance with the law, and all directors, senior managers and other insiders can strictly perform confidentiality obligations during the window period and sensitive period of regular reports and other major matters.

(6) Investor relations management

During the reporting period, the company continued to strengthen information disclosure and inside information management, and strictly followed relevant laws, regulations and the company's internal systems to promote the authenticity, accuracy and completeness of information disclosed without false records, misleading statements or major omissions. The Company’s Securities Affairs Department is responsible for the daily management of investor relations. It actively uses the Shenzhen Stock Exchange’s interactive platform, investor on-site surveys, online performance briefings, investor hotlines, investor emails, etc. to understand and promptly respond to issues of concern to investors, and timely organizes investor opinions and feedback to the Board of Directors to effectively strengthen communication and interaction with investors. It also conducts accurate, timely and clear two-way communication with investors on the company's strategic planning, corporate governance, operating performance, etc., builds a fair and effective communication and interaction bridge between the company, investors and the public, conveys the company's value to investors and the public, and effectively protects the legitimate rights and interests of small and medium-sized investors.

(7) Standardized governance of the company

During the reporting period, the company strictly complied with the requirements of laws, regulations and normative documents such as the "Company Law", "Securities Law", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Listed Company Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other laws, regulations and normative documents. At the same time, combined with the company's actual situation, the company established and improved the company's internal control system and risk prevention and control system, constantly improved the corporate governance structure, promoted the company's standardized operations, strived to improve the level of corporate governance, and effectively protected the interests of all shareholders, especially the majority of small and medium-sized investors.

3. 2026 Board of Directors Work Plan

(1) Improve company rules and regulations and standardize information disclosure

In 2026, the company's board of directors will further improve the corporate governance structure, improve the company's rules and regulations, improve the level of standardized operations, strengthen the construction of the internal control system, continuously improve the risk control system, optimize the company's strategic planning, ensure the sustainable and healthy development of the company, and effectively protect the interests of all shareholders and the company.

At the same time, the board of directors will continue to strictly comply with the requirements of the "Company Law", "Securities Law", "Shenzhen Stock Exchange GEM Stock Listing Rules" and "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and the "Articles of Association" to conscientiously and consciously Fulfill information disclosure obligations, give full play to the supervisory role of independent directors in the company's operations, decision-making, and major matters, and in line with the principles of fairness, impartiality, and openness, truly, accurately, and completely disclose company-related information, improve the quality of information disclosure, enhance company transparency, and effectively protect the rights and interests of investors.

(2) Strengthen investor relations management and safeguard investors’ legitimate rights and interests

In 2026, the board of directors will strengthen investor relations management in strict accordance with relevant laws, regulations and the requirements of the Articles of Association. By regularly organizing investor exchange meetings, performance briefings, investor surveys and other activities, we strengthen communication and exchanges with investors, deepen investors' understanding and recognition of the company, and establish long-term, stable and good interactive relationships between the company and investors, thereby better safeguarding the legitimate rights and interests of investors, especially the legitimate rights and interests of small and medium-sized investors.

(3) Strengthen talent team building and enhance the competitiveness of the core team

In 2026, the company will strengthen the introduction and training of talents, continue to strengthen the construction of talent echelons, increase talent reserves, especially senior talents in R&D and business, further improve the salary assessment system, rationally position human resources at all levels, maximize the effectiveness of the group's overall human resources, meet the company's urgent need for talents in its rapid development, and provide a strong guarantee for the company's sustained and rapid development.

In 2026, the company's board of directors will continue to uphold an attitude of responsibility to all shareholders, promote the company's steady and positive development based on the company's operating needs, and promote the good operation of the company's daily businesses. At the same time, the board of directors will continue to improve standardized operations and governance levels and effectively conduct information disclosure.

Board of Directors of Wuhan Haite Biopharmaceutical Co., Ltd.

April 23, 2026